Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 2, 2002 - Issue 3
Submit an article Journal homepage
33
Views
13
CrossRef citations to date
0
Altmetric
Drug Evaluation

Troxacitabine-based therapy of refractory leukemia

Francis J Giles Section of Developmental Therapeutics, The University of Texas, MD Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030-4095, USA. [email protected]
Pages 261-266 | Published online: 10 Jan 2014

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

R. Swords & F. Giles. (2007) Troxacitabine in acute leukemia. Hematology 12:3, pages 219-227.
Read now
Ronan Swords, Effrosyni Apostolidou & Francis Giles. (2006) Troxacitabine in leukemia. Hematology 11:5-6, pages 321-329.
Read now

Articles from other publishers (11)

Ayaz Mahmood Dar, Shafia Mir, Masrat Jan, Rizwan Nabi, Manzoor Ahmad Gatoo & Shamsuzzaman. (2021) Combined theoretical and experimental studies reveal the newly synthesized pyrimidinones as potential apoptotic agents. Computational Toxicology 17, pages 100145.
Crossref
Rashmi Sharma, Dinesh Y. Gawande, Chander Mohan & Rajesh Kumar Goel. (2016) Synthesis and anticonvulsant activities of functionalized 5-(isoindole-1,3-dione)-pyrimidinones. Medicinal Chemistry Research 25:7, pages 1420-1424.
Crossref
Tadeusz Robak & Agnieszka Wierzbowska. (2009) Current and emerging therapies for acute myeloid leukemia. Clinical Therapeutics 31, pages 2349-2370.
Crossref
Dipti DodiyaK.K., Amit TrivediR.R., Samir JarsaniaH.H., Shailesh VaghasiaJ.J. & Viresh ShahH.H.. (2008) Characterization and biological evaluation of some novel pyrazolo[3',4':4,5]thieno[2,3-d]pyrimidin-8-ones synthesized via the Gewald reaction. Journal of the Serbian Chemical Society 73:7, pages 683-690.
Crossref
Gail J. Roboz, Francis J. Giles, Ellen K. Ritchie, Sandra Allen-Bard, Tania J. Curcio, Meredith A. Wilkes, S. Lani Park, Hagop M. Kantarjian, Stefan Faderl, Farhad Ravandi, Michael J. Kelner & Eric J. Feldman. (2007) Phase I/II Study of Continuous-Infusion Troxacitabine in Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology 25:1, pages 10-15.
Crossref
Nada Orsolic, Francis J. Giles, Henriette Gourdeau, Mirna Golemovic, Miloslav Beran, Jorge Cortes, Emil J Freireich, Hagop Kantarjian & Srdan Verstovsek. (2004) Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation. British Journal of Haematology 124:6, pages 727-738.
Crossref
Francis J. Giles, Eric J. Feldman, Gail J. Roboz, Richard A. Larson, Steven W. Mamus, Jorge E. Cortes, Srdan Verstovsek, Stefan Faderl, Moshe Talpaz, Miloslav Beran, Maher Albitar, Susan M. O’Brien & Hagop M. Kantarjian. (2003) Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leukemia Research 27:12, pages 1091-1096.
Crossref
Francis Giles, Elihu Estey & Susan O'Brien. (2003) Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer 98:10, pages 2095-2104.
Crossref
Preethi Krishnan, Elizabeth A. Gullen, Wing Lam, Ginger E. Dutschman, Susan P. Grill & Yung-chi Cheng. (2003) Novel Role of 3-Phosphoglycerate Kinase, a Glycolytic Enzyme, in the Activation of L-Nucleoside Analogs, a New Class of Anticancer and Antiviral Agents. Journal of Biological Chemistry 278:38, pages 36726-36732.
Crossref
Brian J. P. HuntlyAnthony BenchAnthony R. Green. (2003) Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 102:4, pages 1160-1168.
Crossref
Francis J. GilesHagop M. KantarjianJorge E. CortesGuillermo Garcia-ManeroSrdan VerstovsekStefan FaderlDeborah A. ThomasAlessandra FerrajoliSusan O’BrienJay K. WathenLian-Chun XiaoDonald A. BerryElihu H. Estey. (2003) Adaptive Randomized Study of Idarubicin and Cytarabine Versus Troxacitabine and Cytarabine Versus Troxacitabine and Idarubicin in Untreated Patients 50 Years or Older With Adverse Karyotype Acute Myeloid Leukemia. Journal of Clinical Oncology 21:9, pages 1722-1727.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.